{"id":10848,"date":"2025-05-27T20:13:01","date_gmt":"2025-05-28T00:13:01","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=10848"},"modified":"2025-05-27T20:13:01","modified_gmt":"2025-05-28T00:13:01","slug":"sanofi-acquires-vigil-neuroscience-for-470m-to-boost-alzheimers-drug-pipeline","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/sanofi-acquires-vigil-neuroscience-for-470m-to-boost-alzheimers-drug-pipeline\/","title":{"rendered":"Sanofi Acquires Vigil Neuroscience for $470M to Boost Alzheimer\u2019s Drug Pipeline"},"content":{"rendered":"<p>Sanofi is acquiring Vigil Neuroscience for $470 million to expand its Alzheimer\u2019s drug portfolio, focusing on TREM2-targeting therapies like VG-3927. Learn how this acquisition strengthens Sanofi\u2019s neurology and immunology strategy.<br \/>\nSanofi is acquiring biotechnology company Vigil Neuroscience in a $470 million deal to strengthen its presence in Alzheimer\u2019s disease treatment. The deal includes VG-3927, Vigil\u2019s most advanced experimental drug, which targets the TREM2 protein associated with Alzheimer\u2019s.<br \/>\nSanofi had previously invested $40 million in Vigil, which gives the pharmaceutical giant a strategic edge if Vigil\u2019s TREM2-amplifying drugs move toward licensing. VG-3927 recently completed early-phase trials in both healthy volunteers and Alzheimer\u2019s patients. Vigil\u2019s CEO, Ivana Magov\u010devi\u0107-Liebisch, noted that the buyout will help accelerate development of this potentially transformative treatment.<br \/>\nTREM2 is considered a promising target in Alzheimer\u2019s research because it activates immune responses in the brain when harmful amyloid-beta plaques are present. Malfunctioning TREM2 can lead to inflammation, nerve damage, and cell death\u2014key factors in Alzheimer\u2019s progression. Sanofi\u2019s head of R&#038;D, Houman Ashrafian, emphasized that TREM2 connects immune system dysfunction to neurological diseases, aligning with Sanofi\u2019s expertise in immunology.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\nAlthough Sanofi will not acquire VGL101\u2014another compound from the Vigil platform\u2014those rights will revert to its original licensee, Amgen.<br \/>\nSanofi has traditionally focused on immunology, oncology, and rare diseases, with neurology playing a relatively minor role. Its only marketed neurology drug, Aubagio for multiple sclerosis, accounted for less than 1% of biopharma sales last year. However, the company is actively expanding in this area. Several advanced-stage candidates\u2014including frexalimab for MS, lupus, and type 1 diabetes, riliprubart for chronic inflammatory demyelinating polyneuropathy (CIDP), and tolebrutinib for MS\u2014are in the pipeline. Tolebrutinib, acquired through a $3.7 billion deal with Principia Biopharma in 2020, is currently under FDA review with a decision expected by September.<br \/>\nThe acquisition of Vigil supports Sanofi\u2019s long-term strategy to address critical unmet needs in neurology through immunology-based therapies. Provided a majority of Vigil shareholders approve, the deal is expected to close between July and September. Key investors, including Atlas Venture and Bruce Booth\u2014who collectively own 16.2% of Vigil shares\u2014have already agreed to support the transaction.<br \/>\nIn addition to the $8 per share offer, Vigil shareholders will receive a contingent value right worth $2 per share if VG-3927 achieves its first commercial sale. While Vigil\u2019s stock opened at $14 when it went public in January 2022, its value has since dropped, making this acquisition a compelling exit. Analyst Myles Minter described the outcome as favorable for shareholders, given current market conditions and drug development progress.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\nThis move reinforces Sanofi\u2019s commitment to building a stronger foothold in Alzheimer\u2019s research and broadening its neuroscience portfolio with immune-focused treatments.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi is acquiring Vigil Neuroscience for $470 million to expand its Alzheimer\u2019s drug portfolio, focusing on TREM2-targeting therapies like VG-3927. Learn how this acquisition strengthens Sanofi\u2019s neurology and immunology strategy. Sanofi is acquiring biotechnology company Vigil Neuroscience in a $470 million deal to strengthen its presence in Alzheimer\u2019s disease treatment. The deal includes VG-3927, Vigil\u2019s [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10849,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":{"0":"post-10848","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-commercial"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=10848"}],"version-history":[{"count":1,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10848\/revisions"}],"predecessor-version":[{"id":10850,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10848\/revisions\/10850"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/10849"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=10848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=10848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=10848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}